7-Hydroxystaurosporine

Generic Name: 7-Hydroxystaurosporine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₂₆N_₄O_₄

CAS Number: 112953-11-4

Unique Ingredient Identifier: 7BU5H4V94A

Associated Conditions: -

Associated Therapies: -

Clinical Trials

7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Acute Promyelocytic Leukemia (M3)
Adult Erythroleukemia (M6a)
Adult Pure Erythroid Leukemia (M6b)
Blastic Phase Chronic Myelogenous Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
Secondary Acute Myeloid Leukemia

Interventions: Drug: 7-hydroxystaurosporine
Drug: perifosine
Other: pharmacological study

First Posted Date: 2006-03-13

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00301938

Locations: 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Small Cell Lung Cancer
Extensive Stage Small Cell Lung Cancer

Interventions: Drug: topotecan hydrochloride
Drug: 7-hydroxystaurosporine

First Posted Date: 2004-12-09

Last Posted Date: 2018-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00098956

Locations: 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada

A Phase II Study of UCN-01 in Metastatic Melanoma

Phase 2

Terminated

Conditions: Stage IV Melanoma
Recurrent Melanoma

Interventions: Drug: 7-hydroxystaurosporine
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-11-06

Last Posted Date: 2015-03-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT00072189

Locations: 🇺🇸
UC Davis Cancer Center, Sacramento, California, United States

UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-11-06

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00072267

Locations: 🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

and more 1 locations

7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: 7-hydroxystaurosporine
Drug: cisplatin
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00012194

Locations: 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: carboplatin
Drug: 7-hydroxystaurosporine
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00036777

Locations: 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00045500

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
Frederick Cancer Research and Development Center, Frederick, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: 7-hydroxystaurosporine
Drug: gemcitabine hydrochloride
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00039403

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: 7-hydroxystaurosporine
Drug: topotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2016-06-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 33

Registration Number: NCT00045175

Locations: 🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Phase 1

Completed

Conditions: Advanced Adult Primary Liver Cancer
Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
Recurrent Extrahepatic Bile Duct Cancer
Recurrent Gallbladder Cancer
Recurrent Gastric Cancer
Recurrent Gastrointestinal Carcinoid Tumor
Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
Carcinoma of the Appendix
Gastrointestinal Stromal Tumor
Estrogen Receptor-negative Breast Cancer

Interventions: Drug: 7-hydroxystaurosporine
Drug: irinotecan hydrochloride
Other: diagnostic laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT00031681

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy